Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948262 | 0.91 | KEAP1 (0.44) | ALDH1A1KEAP1SMN1; SMN2KDM4ESIGMAR1 | |
| SCHEMBL16432068 | 0.84 | HRH3 (0.34) | SIGMAR1CYP1A2HRH3CYP3A4 | |
| SCHEMBL17080296 | 0.72 | NOS3 (0.31) | — | |
| SCHEMBL2353670 | 0.72 | KEAP1 (0.38) | ALDH1A1KEAP1SMN1; SMN2KDM4EGLA | |
| SCHEMBL235080 | 0.71 | KDM4E (0.65) | ALDH1A1KEAP1SMN1; SMN2KDM4EGLA | |
| SCHEMBL16975334 | 0.70 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL1557723 | 0.70 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL1456338 | 0.69 | HTT (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM4ESIGMAR1 | |
| SCHEMBL11856358 | 0.68 | KDM4E (0.70) | ALDH1A1KEAP1SMN1; SMN2KDM4EGLA | |
| SCHEMBL10913328 | 0.68 | KDM4E (0.70) | ALDH1A1KEAP1SMN1; SMN2KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | claimed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | claimed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| US-11591329-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | claimed |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | claimed |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | claimed |
| WO-2022261160-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | claimed |
| EP-3980404-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114040912-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2016113170-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | claimed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | claimed |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | US | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | claimed |
| WO-2013085957-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | ALDH1A1 593/4885KEAP1 2081/4885SMN1; SMN2 4199/4885 |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ALDH1A1 879/4885KEAP1 2710/4885SMN1; SMN2 4438/4885 |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | ALDH1A1 4193/4885KEAP1 685/4885SMN1; SMN2 3154/4885 |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | MAP3K20, MAP3K6, MAP3K1 | ALDH1A1 2087/4885KEAP1 882/4885SMN1; SMN2 385/4885 |
| US-11591329-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ALDH1A1 802/4885KEAP1 1171/4885SMN1; SMN2 3985/4885 |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, PLIN1 | ALDH1A1 799/4885KEAP1 1748/4885SMN1; SMN2 2319/4885 |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | ALDH1A1 467/4885KEAP1 673/4885SMN1; SMN2 4636/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ALDH1A1 879/4885KEAP1 2710/4885SMN1; SMN2 4438/4885 |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | ALDH1A1 879/4885KEAP1 2710/4885SMN1; SMN2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.